NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free UTHR Stock Alerts $239.29 +4.82 (+2.06%) (As of 10:44 AM ET) Add Compare Share Share Today's Range$233.28▼$239.7450-Day Range$214.16▼$249.5152-Week Range$204.44▼$261.54Volume85,572 shsAverage Volume432,121 shsMarket Capitalization$11.26 billionP/E Ratio12.06Dividend YieldN/APrice Target$294.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside23.0% Upside$294.25 Price TargetShort InterestBearish11.28% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.55Based on 27 Articles This WeekInsider TradingSelling Shares$31.38 M Sold Last QuarterProj. Earnings Growth5.56%From $23.76 to $25.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.41 out of 5 starsMedical Sector49th out of 909 stocksPharmaceutical Preparations Industry17th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.28% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in United Therapeutics has recently increased by 154.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.1 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for United Therapeutics this week, compared to 6 articles on an average week.Search Interest16 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 129% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,379,925.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 5.56% in the coming year, from $23.76 to $25.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 12.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.59.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 12.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 173.75.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesApril 24, 2024 | insidertrades.comMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockApril 18, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in StockApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,512.00 in StockApril 13, 2024 | insidertrades.comMartine A. Rothblatt Sells 13,800 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockApril 10, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 5,060 Shares of StockApril 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 15,000 SharesApril 6, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 15,000 Shares of StockApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 5, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $1,394,220.00 in StockMarch 30, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 325 Shares of StockMarch 30, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 14,125 SharesApril 24, 2024 | businesswire.comUnited Therapeutics Announces World's First Successful Xenothymokidney TransplantApril 24, 2024 | businesswire.comUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024April 24, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of StockApril 24, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from AnalystsApril 21, 2024 | investing.comUnited Therapeutics CEO Martine Rothblatt sells $1.7m in stockApril 21, 2024 | finance.yahoo.comUnited Therapeutics Corporation (UTHR)April 20, 2024 | americanbankingnews.comLeerink Partnrs Brokers Cut Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)April 18, 2024 | markets.businessinsider.comUnited Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform RatingApril 18, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) to Post Q1 2024 Earnings of $5.93 Per Share, Leerink Partnrs ForecastsApril 16, 2024 | investing.comUnited Therapeutics CEO Martine Rothblatt sells shares worth over $1.7 millionApril 16, 2024 | finance.yahoo.comUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceApril 12, 2024 | finance.yahoo.comInnovation in Healthcare: HTEC’s Q1 2024 Index RebalanceApril 11, 2024 | investing.comUnited Therapeutics chairperson & CEO sells $4.73m in stockApril 6, 2024 | investing.comUnited Therapeutics EVP sells over $1.3m in company stockApril 6, 2024 | finance.yahoo.comInsider Sell: Chairperson & CEO Martine Rothblatt Sells 30,000 Shares of United ...See More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$294.25 High Stock Price Target$330.00 Low Stock Price Target$215.00 Potential Upside/Downside+25.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$19.84 Trailing P/E Ratio11.82 Forward P/E Ratio9.87 P/E GrowthN/ANet Income$984.80 million Net Margins42.31% Pretax Margin54.75% Return on Equity17.72% Return on Assets14.47% Debt Debt-to-Equity Ratio0.05 Current Ratio4.41 Quick Ratio4.28 Sales & Book Value Annual Sales$2.33 billion Price / Sales4.74 Cash Flow$22.12 per share Price / Cash Flow10.60 Book Value$127.35 per share Price / Book1.84Miscellaneous Outstanding Shares47,060,000Free Float41,177,000Market Cap$11.03 billion OptionableOptionable Beta0.52 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonSenior Vice President of Product DevelopmentMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSBioMarin PharmaceuticalNASDAQ:BMRNMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 2,905 shares on 4/24/2024Ownership: 0.172%Amalgamated BankSold 1,446 shares on 4/23/2024Ownership: 0.059%Louisiana State Employees Retirement SystemBought 300 shares on 4/23/2024Ownership: 0.029%Nations Financial Group Inc. IA ADVBought 398 shares on 4/23/2024Ownership: 0.003%Fifth Third BancorpSold 1,126 shares on 4/23/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 9 Wall Street research analysts have issued 1-year price targets for United Therapeutics' shares. Their UTHR share price targets range from $215.00 to $330.00. On average, they anticipate the company's stock price to reach $294.25 in the next year. This suggests a possible upside of 23.0% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2024? United Therapeutics' stock was trading at $219.89 at the beginning of 2024. Since then, UTHR stock has increased by 8.8% and is now trading at $239.29. View the best growth stocks for 2024 here. Are investors shorting United Therapeutics? United Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 154.7% from the March 15th total of 1,920,000 shares. Based on an average daily trading volume, of 431,700 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.3% of the company's shares are sold short. View United Therapeutics' Short Interest. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. The biotechnology company earned $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a trailing twelve-month return on equity of 17.72% and a net margin of 42.31%. United Therapeutics's quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.67 EPS. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Biotechnology & Genome ETF (PBE), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG) and First Trust Health Care AlphaDEX Fund (FXH). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.21%), Los Angeles Capital Management LLC (0.19%), Assenagon Asset Management S.A. (0.17%), Atwood & Palmer Inc. (0.14%) and Raymond James & Associates (0.06%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
